1456907-36-0

Upstream product

• 1456906-73-2 6-O-methanesulfonyl-2-(N-4-phenylbenzenecarbonyl)amino-N-(4-chlorobenzyl)hexaneamide 
• 155-09-9 trans-2-phenylcyclopropylamine 
• 1456906-61-8 6-(N-tert-butoxycarbonyl)amino-2-(n-4-phenylbenzenecarbonyl)amino-N-(4-chlorobenzyl)hexaneamide 
• 1456906-56-1 2-amino-6-(N-tert-butoxycarbonyl)amino-N-(4-chlorobenzyl)hexaneamide 
• 1456906-53-8 6-(N-tert-butoxycarbonyl)amino-2-(n-fluorenylmethoxycarbonyl)amino-N-(4-chlorobenzyl)hexaneamide 
• 71989-26-9 Fmoc-Lys(tert-butoxycarbonyl) 
• 104-86-9 4-chlorobenzylamine 

Relevant academic research and scientific papers

LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE

A primary object of the present invention is to provide a novel compound having LSD1-selective inhibitory activity and having an antitumor/anticancer action, an antiviral action, and the like. As means for achieving such object, provided is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: [in the formula, R1 to R5, A, and *1 to *3 are as defined in Description].

Lysine-specific demethylase 1-selective inactivators: Protein-targeted drug delivery mechanism

Drug drop off: Given that lysine-specific demethylase 1 (LSD1) could be potently and selectively inactivated by delivering phenylcyclopropylamine (PCPA), a weak and nonselective LSD1 inhibitor, directly to the enzyme's active site, a novel series of LSD1 inactivators (1) were designed. Biological and mechanistic studies indicate that 1 inhibits LSD1 potently and selectively. Copyright